Journal Article

Safety, tolerability and immunogenicity of V934/V935 hTERT vaccination in cancer patients with selected solid tumors: a phase I study

Bagchi, Ansuman, Aurisicchio, Luigi, Sheloditna, Rose, Fridman, Arthur, Ciliberto, Gennaro, Chiappori, Alberto, Mauro, David

2020

Overview

Background Human telomerase reverse transcriptase (hTERT) is an antigen that may represent a target for a novel anti-cancer strategy. A pilot, phase I study tested the safety and feasibility of a prime-boost immunization regimen based on V935, an adenoviral type 6 vector vaccine expressing a modified version of hTERT, administered alone or in combination with V934, a DNA plasmid that also expresses the same antigen and is delivered using the electroporation injection technique. Methods Treatments: Group #1 received two doses (low-dose: 0.5 × 10 9 vg, and high-dose: 0.5 × 10 11 vg) of V935 followed by a 4-week observation period. Group #2 received three doses of V934-electroporation and two doses of V935 following a 4-week observation period. Doses were low-dose V934 (0.25 mg of plasmid) with low-dose V935 (0.5 × 10 9 vg); high-dose V934 (2.5 mg of plasmid) with high-dose V935 (0.5 × 10 11 vg). Group #3 received five doses of V934-EP and two doses of V935: V934 was administered IM every 2 weeks for five doses. Following a 4-week observation period, V935 was administered IM every 2 weeks for two doses followed by a 4-week observation period. One (1) dose level was tested in treatment group #3: high-dose V934 (2.5 mg of plasmid), in combination with high-dose V935 (0.5 × 1011 vg). Immunogenicity was measured by ELISPOT assay and three pools of peptides encompassing the sequence of hTERT. Results In total, 37 patients affected by solid tumors (prostate cancer in 38%) were enrolled. The safety profile of different regimens was good and comparable across groups, with no severe adverse events, dose-limiting toxicities or treatment discontinuations. As expected, the most common adverse events were local reactions. A significant increase in ELISPOT responses against hTERT peptide pool 2 was observed (p < 0.01), while no evidence of boosting was observed for peptide pools 1 and 3. This was also evident for group #1 and #2 separately. In patients with prostate cancer, there was a significant increase in ELISPOT response against hTERT peptide pool 2 following immunization (p < 0.01), regardless of previous therapy, immunosuppressing agents, or adenoviral type 6 titers at screening. Conclusion Our results suggest the safety and feasibility of V934/V935 hTERT vaccination in cancer patients with solid tumors Trial Registration Name of the registry: ClinicalTrial.gov Trial registration number: NCT00753415 Date of registration: 16 September 2008 Retrospectively registered URL of trial registry record: https://clinicaltrials.gov/ct2/results?cond=&term=NCT00753415&cntry=&state=&city=&dist=

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Adenoviridae - genetics / Adenovirus / Adenoviruses / Biomedical and Life Sciences / Biomedicine / Cancer / Cancer patients / Cancer vaccination / Cancer vaccines / Care and treatment / Clinical medicine / Combination strategies / Cytomegalovirus / Deoxyribonucleic acid / DNA / Electroporation / Enrollments / Enzyme-linked immunosorbent assay / Gene expression / Genetic Vectors / Health aspects / hTERT / Humans / Immunogenicity / Male / Medicine/Public Health / Neoplasms - therapy / Neutropenia / Patient outcomes / Peptides / Prime-boost immunization / Prostate cancer / Proteins / RNA-directed DNA polymerase / Safety / Solid tumors / Telomerase / Telomerase reverse transcriptase / Testing / Tumors / Vaccination / Vaccines / Viral Vaccines